JAF: Advisory Group Member, Astra Zeneca, Ad Hoc Consultant, Novartis Pharmaceuticals. Disclosure Not Provided: MJE, NP
Although tremendous progress has been made in the development of new therapies for cancer, a significant problem in the long-term prognosis for patients is the development of therapeutic resistance. Over the past 20 years, significant progress has been made in understanding the genes and signaling pathways which drive human cancers, including those in the endocrine system. Despite the development of drugs which can target these pathways, treatment responses are often short-lived and recurrent tumors become more and more difficult to treat. This symposium is aimed at reviewing the current state of the art in our understanding of mechanisms which contribute to the development of resistance to standard and targeted therapies for cancer. With a better understanding of these processes, it remains the hope that newer and more effective therapies for treating cancer can eventually be developed.